Literature DB >> 15274366

Neoangiogenesis in patients with gastric carcinoma in relation to the expression of vascular endothelial growth factor and thymidine phosphorylase.

Shunichi Tsujitani1, Hiroaki Saito, Yoshihiko Maeta, Kenichi Yamaguchi, Shigeru Tatebe, Akira Kondo, Nobuaki Kaibara.   

Abstract

BACKGROUND: We investigated the prognostic significance of microvessel density and the relationship between the expression of vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP), and angiogenesis in patients with gastric carcinoma.
MATERIALS AND METHODS: The expression of VEGF and TP, and the microvessel density were examined by immunohistochemistry in patients with gastric carcinoma invading the serosa.
RESULTS: The prognosis of patients with low microvessel density in the cancerous tissue was significantly better than that of patients with high microvessel density. A multivariate analysis showed that microvessel density, lymph node metastasis and tumor size were independent prognostic indicators. VEGF was expressed in tumor cells and TP was expressed in both tumor cells and infiltrating cells. VEGF expression in tumor cells and TP expression in infiltrating cells significantly correlated with microvessel density. However, microvessel density was not correlated with TP expression in tumor cells. Combined analysis based on VEGF expression in tumor cells and TP expression in infiltrating cells revealed that microvessel density was the highest in VEGF-positive and TP-positive tumors and the lowest in VEGF-negative and TP-negative tumors. Microvessel density is an independent prognostic indicator in patients with gastric carcinoma invading the serosa.
CONCLUSION: VEGF expression in tumor cells and TP expression in infiltrating cells may indicate the microvessel density.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15274366

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Evidence for angiogenesis-independent contribution of VEGFR1 (FLT1) in gastric cancer recurrence.

Authors:  Evgeny N Suspitsin; Aniruddh Kashyap; Kseniya V Shelekhova; Anna P Sokolenko; Ekatherina Sh Kuligina; Aglaya G Iyevleva; Alexandr V Kornilov; Volker Ehemann; Grigoriy A Yanus; Svetlana N Aleksakhina; Elena V Preobrazhenskaya; Olga A Zaitseva; Olga S Yatsuk; Valeriy F Klimashevsky; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Med Oncol       Date:  2013-06-26       Impact factor: 3.064

2.  Astrocytic TYMP and VEGFA drive blood-brain barrier opening in inflammatory central nervous system lesions.

Authors:  Candice Chapouly; Azeb Tadesse Argaw; Sam Horng; Kamilah Castro; Jingya Zhang; Linnea Asp; Hannah Loo; Benjamin M Laitman; John N Mariani; Rebecca Straus Farber; Elena Zaslavsky; German Nudelman; Cedric S Raine; Gareth R John
Journal:  Brain       Date:  2015-03-23       Impact factor: 13.501

3.  Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma.

Authors:  Jin-Lian Chen; Jing Hong; Jin-Lai Lu; Ming-Xiang Chen; Wei-Xiong Chen; Jin-Shui Zhu; Ni-Wei Chen; Guo-Qiang Chen; Jian-Guo Geng
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

Review 4.  The dual role of thymidine phosphorylase in cancer development and chemotherapy.

Authors:  Annelies Bronckaers; Federico Gago; Jan Balzarini; Sandra Liekens
Journal:  Med Res Rev       Date:  2009-11       Impact factor: 12.944

5.  Research development of the relationship between thymidine phosphorylase expression and colorectal carcinoma.

Authors:  Dian-Jun Ye; Ji-Min Zhang
Journal:  Cancer Biol Med       Date:  2013-03       Impact factor: 4.248

Review 6.  Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options.

Authors:  Daniela Rodrigues; Adhemar Longatto-Filho; Sandra F Martins
Journal:  Biomed Res Int       Date:  2016-08-01       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.